Program savings associated with switching testosterone intramuscular injections to topical gel in HIV infected males

References

• Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002;34:248–59
   Google Scholar
• Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988;84:611–6
   PubMed Web of Science ®Google Scholar
• Kuhne, CA, Heufelder AE, Hofbauer LC. Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 2001;6:2–9
   Google Scholar
• Bhasin S. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerotic progression. Clin Infect Dis 2003;37:S142–9
   PubMedGoogle Scholar
• Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body mass correlates with androgen levels in hypogonadal men with acquired-immunodeficiency syndrome and wasting. Clin Endocrinol Metab 1996;81:4051–8
   Google Scholar
• Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, et al. Effects of testosterone replacement with a non-genital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998;83:3155–62
   Google Scholar
• Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with AIDS wasting syndrome: a randomized, double-blind, placebo controlled trial. Ann Intern Med 1998;129:18–26
   PubMed Web of Science ®Google Scholar
• Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in eugonadal men with acquired immunodeficiency wasting syndrome. J Clin Endocrinol Metab 2001;86:2020–6
   PubMed Web of Science ®Google Scholar
• Clay PG, Lam AI. Testosterone replacement for bone loss prevention in HIV-infected males. Ann Pharmacother 2003;37:582–5
   PubMed Web of Science ®Google Scholar
• Sifton DW, Murray L, Kelly GL. Testoderm TTS patches. Physicians drug reference, 55th ed.Montvale: Medical Economics Company; 2001.p. 535–6
   Google Scholar
• Androgel Package Insert. Unimed Pharmaceuticals, Inc, A Solvay Company, Inc. Company; Deerfield, IL. Issued 9/01
   Google Scholar
• Oxandrin Package Insert. BTG Pharmaceuticals; Iselin, NJ; Issued 8/01
   Google Scholar
• Sifton DW, Murray L, Kelly GL. Testoderm TTS patches. Physicians drug reference 55th ed. Montvale: Medical Economics Company; 2001. p. 1075–6
   Google Scholar
• Drugstore.com Price Finder. http://www.drugstore.com/ pharmacy/prices [accessed 27 November 2002]
   Google Scholar
• Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States. Clin Infect Dis 2002;35:606–10
   Google Scholar
• Smith SR, Buchanan RJ. The AIDS drug assistance programs and coverage of HIV-related medications. Ann Pharmacother 2001;35:155–66
   PubMed Web of Science ®Google Scholar
• Johri M. Paltiel A, Goldie SJ, Freedberg KA. State AIDS Drug Assistance programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care 2002;40:429–41
   Google Scholar
• Green MJ, Fong S, Mauger DT, Ubel PA. Rationing HIV medications: what do patients and the public think about allocation policies? J Acquir Immune Defic Synd 2001;26:56–62
   PubMed Web of Science ®Google Scholar
• Buchanan RJ, Chakravorty BJ, Smith SR. Eligibility policies for the state AIDS drug assistance programs. Soc Work Health Care 2001;32:81–104
   Google Scholar
• Finkler SA, Knickman JR, Hendrickson G, Lipkin M, Thompson WG. A comparison of work-sampling and time-and-motion techniques for studies in health services research. Health Serv Res 1993;28:577–97
   Google Scholar
• Bensing JM, Roter DL, Hulsman RL. Communication patterns of primary care physicians in the United States and the Netherlands. J Gen Intern Med 2003;18:335–42
   Google Scholar
• Hu P, Reuben DB. Effects of managed care on the length of time that elderly patients spend with physicians during ambulatory visits: National Ambulatory Medical Care Survey. Med Care 2002;40:606–13
   PubMed Web of Science ®Google Scholar
• Fauci AS, Bartlett JG, Goosby EP, Kates J, editors. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents – 14 July 2003. http://www.aidsinfo.nih.gov/guidelines [Accessed on 8 October 2003]
   Google Scholar
• Freedberg K. Cost-effectiveness of HAART. Program and abstracts of the 1st IAS conference on HIV pathogenesis and treatment; July 8–11, 2001; Buenos Aires, Argentina [Abstract No.IL4]
   Google Scholar
• Mathews WC, Mar-Tang M, Ballard C, et al. Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care STDs 2002;16:157–72
   PubMed Web of Science ®Google Scholar
• Kopicko JJ, Momodu I, Adedokun A, Hoffman M, Clark RA, Kissinger P. Characteristics of HIV-infected men with low serum testosterone levels. Int J STD AIDS 1999;10:817–20
   PubMed Web of Science ®Google Scholar